Developing comprehensive screening for early-stage cancer is the key to saving the most lives.
Although multi-cancer early detection (MCED) tests are still being researched and lack FDA approval, several are commercially available for consumers who are willing to pay out-of-pocket. Individuals can ask their doctor to order the Galleri blood test from Grail, or they can opt for a whole-body MRI from companies like Prenuvo or Ezra, which often cost $2,000 or more.
Soon, consumers will have another — and rather unique—way to screen for…
